These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29675797)

  • 1. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
    Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
    Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
    Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
    Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
    Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
    Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
    Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
    Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
    Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.
    Peng XV; Ayyagari R; Lubwama R; Shi L; Price-Haywood EG; Hollander P; Fonseca V
    Diabetes Ther; 2020 Apr; 11(4):995-1005. PubMed ID: 32112204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
    Lin J; Lingohr-Smith M; Fan T
    Clinicoecon Outcomes Res; 2017; 9():19-29. PubMed ID: 28053550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.
    Ken-Opurum J; Srinivas SSS; Jain D; Shah T; Samnaliev M; Dex T; Charland S; Revel A; Preblick R
    Diabetes Ther; 2023 Dec; 14(12):2109-2125. PubMed ID: 37801225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
    Rosenstock J; Ampudia-Blasco FJ; Lubwama R; Peng XV; Boss A; Shi L; Fonseca V
    Diabetes Obes Metab; 2020 Dec; 22(12):2295-2304. PubMed ID: 32729183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes.
    Miyoshi H; Baxter M; Kimura T; Hattori M; Morimoto Y; Marinkovich D; Tamiwa M; Hirose T
    Diabetes Ther; 2021 May; 12(5):1341-1357. PubMed ID: 33730337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin.
    Buysman EK; Fan T; Blauer-Peterson C; Miller-Wilson LA
    Endocrinol Diabetes Metab; 2018 Jul; 1(3):e00019. PubMed ID: 30815554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.